Open AccessAbstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)
Author(s) -
John Crown,
William Jacot,
Denis M. Collins,
Linda Coate,
Anna Barbro Sætersdal,
Michael J. Kennedy,
Catherine M. Kelly,
B. Cantos Sánchez de Ibargüen,
Raquel Andrés Conejero,
Luís Costa,
Margarida Brito,
Maccon M. Keane,
Pedro Sánchez Rovira,
Miguel Martín,
Miriam O’Connor,
Manuel Ramos Vázquez,
Elena Álvarez,
Séamus O’Reilly,
Johanna Mattson,
Laura Lopez,
Álvaro Rodríguez Lescure,
Esperanza J. Carcache de Blanco,
Coralia Bueno Muíño,
Brian Moulton,
Norma O’Donovan,
Andrés Hernando,
Marc Nolan,
Imelda Parker,
Giuseppe Gullo,
Bryan T. Hennessy
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct212
Subject(s) - medicine , metastatic breast cancer , lapatinib , trastuzumab , clinical endpoint , breast cancer , oncology , population , chemotherapy , cancer , neutropenia , response evaluation criteria in solid tumors , surgery , progressive disease , randomized controlled trial , environmental health